7. REFERENCES
(1) Neuhaus P, Klupp J, Langrehr J M. mTOR Inhibitors: An Overview. Liver Transpl. 2001;7(6):473-84. https://doi.org/10.1053/jlts.2001.24645
(2) Shen L-J, Lin Wu F-L. Nanomedicines in renal transplant rejection- focus on sirolimus. Int. J Nanomedicine, 2007;2(1):25-32. https://doi.org/10.2147/nano.2007.2.1.25
(3) Mahalati K, Kahan BD. Clinical Pharmacokinetics of sirolimus.Clin. Pharmacokinet. 2001;40:573-585. https://doi.org/10.2165/00003088-200140080-00002
(4) Simamora P, Alvarez J M, Yalkowsky S H. Solubilization of Rapamycin.Int J Pharm. 2001;213(1-2):25-9. https://doi.org/10.1016/s0378-5173(00)00617-7
(5) Sun M, Si L, Zhai X, et.al. The Influence of Co-Solvents on the Stability and Bioavailability of Rapamycin Formulated in Self-Microemulsifying Drug Delivery Systems. Drug Dev Ind Pharm.2011;37(8):986-94. https://doi.org/10.3109/03639045.2011.553618
(6) Grinfield A A, Caufield C E, Schiksnis R A, Mattes J F, Chan K W. Acid Catalyzed Functionalization of rapamycin. Tetrahedron Lett.1994;35(37):6835-6838. https://doi.org/10.1016/0040-4039(94)85017-8
(7) Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, Borchert H-H.J Ocul Pharmacol Ther. 2007;23(3):292-303. https://doi.org/10.1089/jop.2006.130
(8) Lloberas N, Torras J, Aplerovich G, Cruzado J M, et.al. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transpl.2008;23(10):3111-3119. https://doi.org/10.1093/ndt/gfn223
(9) Nguyen Q D, Ibrahim M A, Watters A, et.al. Ocular Tolerability and Efficacy of Intravitreal and Subconjunctival Injections of Sirolimus in Patients With Non-Infectious Uveitis: Primary 6-month Results of the SAVE study. J Ophthalmic Inflamm Infect . 2013;3(1):32. https://doi.org/10.1186/1869-5760-3-32
(10) Dugel P U, Blumenkranz M S, Haller J A, et.al. A Randomized, Dose-Escalation Study of Subconjunctival and Intravitreal Injections of Sirolimus in Patients With Diabetic Macular Edema. J Ophtalmol.2012;119(1):124-31. https://doi.org/10.1016/j.ophtha.2011.07.034
(11) Bhatt N, Dalal M, Tucker W, Obiyor D, Nussenblatt R, Nida Sen H. Subconjunctival Sirolimus in the Treatment of Autoimmune Non-Necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am J Ophtalmol. 2015;159(3):601-6. https://doi.org/10.1016/j.ajo.2014.12.009
(12) Shah M, Edman M C, Janga S R, et.al. A Rapamycin-Binding Protein Polymer Nanoparticle Shows Potent Therapeutic Activity in Supressing Autoimmune Dacryoadenitis in a Mouse Model of Sjogren´s Syndrome.J Control Release. 2013;171(3):269-79. https://doi.org/10.1016/j.jconrel.2013.07.016
(13) Kahan B D. Sirolimus: A Comprehensive Review. Expert Opin Pharmacother. 2001;2(11):1903-17
(14) Douglas LC, Yi N Y, Davis J L, Salmon J H, Gilger B C, Ocular Toxicity and Distribuition of Subconjunctival and Intravitreal Rapamycin in Horses. J Vet Pharmacol Ther. 2008;31(6):511-6. https://doi.org/10.1111/j.1365-2885.2008.00986.x
(15) De Almeida Manzano R P, Peyman G A, Khan P, et.al. Testing Intravitreal Toxicity of Rapamycin in Rabbit Eyes. Arq Bras Oftalmol. 2009;72(1):18-22. https://doi.org/10.1590/s0004-27492009000100004
(16) WR Gombotz, B.5- Liposomes A2- Ratner, Buddy D, in: A.S Hoffman, F.J Schoen, J.E Lemons (Eds.), Biomaterials Science (Third Edition), Academic Press 2013, pp. 1039-1041.
(17) Patel P B, Shastri D H, Shelat P K, Shukla A K. Ophthalmic Drug Delivery System: Challenges and Approaches. Sys Rev Pharm.2010;1(2):113-120.
(18) Pattni B S, Chupin V V, Torchilin V P. New developments in Liposomal Drug Delivery. Chem Rev . 2015;115(19):10938-66. https://doi.org/10.1021/acs.chemrev.5b00046
(19) Kaur I P, Garg A, Singla A K, Aggarwal D. Vesicular Systems in Ocular Drug Delivery: An Overview. Int J Pharm. 2004;269(1):1-14. https://doi.org/10.1016/j.ijpharm.2003.09.016
(20) Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev. 1995;16(1):75-93. https://doi.org/10.1016/0169-409X(95)00016-Z
(21) Bourlais C L, Acar , Zia H, Sado P A, Needham T, Leverge R. Ophthalmic Drug Delivery Systems—Recent Advances. Prog Retin Eye Res. 1998;17(1):33-58. https://doi.org/10.1016/s1350-9462(97)00002-5
(22) Barza M, Baum J, Tremblay C, Szoka F, D´Amico D J. Ocular Toxicity of Intravitreally Injected Liposomal Amphotericin B in Rhesus Monkeys.Am J Ophtlamol. 1985;100(2):259-63. https://doi.org/10.1016/0002-9394(85)90791-3
23) M R Mozafari, C J Reed, C Rostron. Cytotoxicity evaluation of anionic nanoliposomes and nanolipoplexes prepared by the heating method without employing volatile solvents and detergents.” Pharmazie2007;62(3):205-9. PMID: 17416197
(24) Linares-Alba M A, Gómez-Guajardo M B, Furtado-Fonzar J, Brooks D E, García-Sánchez G A, Bernad-Bernad M J. Preformulation Studies of a Liposomal Formulation Containing Sirolimus for the Treatment of Dry Eye Disease. J Ocul Pharmacol Ther.2016;32(1):11-22.
https://doi.org/10.1089/jop.2015.0032
(25) García-Sánchez G A, & Bernard M J B. 2017. U.S Patent No. 9,801,862. Washington, DC: U.S. Patent and Trademark Office.
26) Murilo-Bautista A, Nogura-Louzada R, Crunivel Isaac D L, et.al. In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus. Int. J. Retin. Vitr. 2019; 5(35).
(27) OECD, Test No. 474 Mammalian Erithrocyte Micronucleus Test, OECD Publishing, 2014
(28) Batista-Duharte A, Murillo G J, Pérez U M, et.al. The Hen´s Egg Test on Chorioallantoic Membrane: An Alternative Assay for the Assesment of the Irritating Effect of Vaccine Adjuvants. Int J Toxicol.2016;35(6):627-633. https://doi.org/10.1177/1091581816672187
(29) FEUM, Prueba de pirógenos, in: FEUM (Ed.), Suplemento de dispositivos médicos, Secretaría de Salud, México 2001.
(30) Demircigil G C, Aykanat B, Fidan K, et.al. Micronucleus Frequencies in Peripheral Blood Lymphocytes of Children With Chronic Kidney Disease.Mutagenesis . 2011;26(5):643-50. https://doi.org/10.1093/mutage/ger027
(31) Kempen J H, Gangaputra S, Helzlsouer K J. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: A critical assesment of evidence. Am J Ophtalmol. 2008;146(6):802-12. https://doi.org/10.1016/j.ajo.2008.04.035
(32) Blagosklonny M V. Molecular Damage in Cancer: An Argument for mTOR-driven Aging. Aging (Albany NY). 2011;3(12):1130-41. https://doi.org/10.18632/aging.100422
(33) Tavaszi J, Budai P. The Use of HET-CAM Test in Detecting Ocular Irritation. Commun Agric Apll Biol Sci. 2007;72(2):137-41.
(34) Parnham M J, Wetzig H. Toxicity Screening of Liposomes. Chem Phys Lipids. 1993:64(1-3):263-74. https://doi.org/10.1016/0009-3084(93)90070-j
(35) Food and Drug Administration Center for Veterinary Medicine (2008). Guidance for Industry: Target Animal Safety for Veterinary Pharmaceutical Products. VICH GL43.
(36) Shah M, Edman M C, Janga S R, et.al. Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjogren´s Syndrome.Invest Ophthalmol Vis Sci. 2017;58(1):372-385. https://doi.org/10.1167/iovs.16-19159
(36) H.L. Ioachim, L.J. Medeiros, Ioachim’s Lymph Node Pathology, Wolters Kluwer Health/Lippincott Williams & Wilkins2009.
(37) S.W. Barthold, S.M. Griffey, D.H. Percy, Pathology of Laboratory Rodents and Rabbits, Wiley2016.
(38) Sunohara-Neilson J, Brash M, Carman S, Nagy E, Turner P V. Experimental Infection of New Zealand White Rabbits (Oryctolagus cuniculi) with Leporid herpesvirus 4. Comp Med.2013;63(5):422-430. PMID 24210019
(39) P.J. Manning, D.H. Ringler, C.E. Newcomer, The Biology of the Laboratory Rabbit, Elsevier Science2014.
(40) Erdine S, Yucel A, Ozyalçin, et.al. Neurotoxicity of Midazolam in the Rabbit. Pain. 1999;80(1-2):419-23. https://doi.org/10.1016/s0304-3959(98)00240-1
(41) Cox J C, Hamilton R C, Attwood H D. An Investigation of the Route and Progression of Encephailtozzon Cuniculi Infection in Adult Rabbits.J Protozool. 1979;26(2):260-5. https://doi.org/10.1111/j.1550-7408.1979.tb02776.x.
(42) Pellett, Sarah. ”Encephalitozoon cuniculi in rabbits: an overview.”Companion Animal 21.5 (2016): 300-305.
(43) Kunzel F, Joachim A. Encephalitozoonosis in Rabbits.Parasitol Res. 2010;106(2):299-309. https://doi.org/10.1007/s00436-009-1679-3
(44) Cox J C, Gallichio H A. Serological and Histological Studies on Adult Rabbits With Recent, Naturally Acquired Encephalitozoonosis.Res Vet Sci. 1978;24(2):260-1. PMID:653124
(45) Everds N E, Snyder P W, Bailey K L. Interpreting Stress Responses During Routine Toxicity Studies: A Review of the Biology, Impact, and Assessment. Toxicol Pathol. 2013;41(4):560-614. https://doi.org/10.1177/0192623312466452
46) Özkan Ö, Alcigir ME. Subacute Stage of Encephalitozoon cuniculi Infection in Eye Lesions of Rabbit in Turkey. Iran J Parasitol . 2018;13(2):301-309.
(47) Morrisett J D, Abdel-Fattah G, Hoogeveen R, et.al. Effects of Sirolimus on Plasma Lipids, Lipoprotein Levels, and Fatty Acid Metabolism in Renal Transplant Patients. J Lipid Res.2002;43(8):1170-80. PMID:12177161
(48) Falke L L, van Vuuren S H, Kazazi-Hyseni F, et.al. Local Therapeutic Efficacy With Reduced Systemic Side Effects by Rapamycin-Loaded Subcapsular Microspheres. Biomaterials.2015;42:151-60. https://doi.org/10.1016/j.biomaterials.2014.11.042
(49) Aguirre S A, Gukasyan H J, Younis H S, Huang W. Safety Assessment of Formulation Vehicles Following Intravitreal Administration in Rabbits. Pharm Res. 2018;35(9):173. https://doi.org/10.1007/s11095-018-2450-1
(50) Mochizuki K, Torisaki M, Kawasaki K. Retinal toxicity of antibiotics: Evaluation by electroretinogram. Doc Ophthalmol.1988;69:195-202
(51) Patel S, Barnett J M, Kim S J. Retinal Toxicity of Intravitreal Polyethylene Glycol 400. J Ocul Pharmacol Th. 2016;32(2). https://doi.org/10.1089/jop.2015.0069
(52) Brandao-De Paiva M R, Almeida-Lage N, Andrade M C, et.al. Toxicity and in Vivo Release Profile of Sirolimus From Implants Into the Vitreous of Rabbits´Eyes. Doc Ophthalmol. 2019;138(1):3-19. https://doi.org/10.1007/s10633-018-9664-8
(53) Okamoto T, Ozawa Y, Kamoshita M. The Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-κB Axis During Retinal Inflammation. PLoS One. 2016;11(1):e0146517. https://doi.org/10.1371/journal.pone.0146517.